Helus Pharma elects eight directors, changes name Oct. 1

• Shareholders elected Grant Froese, Theresa Firestone, Mark Lawson, Eric So, Freda Lewis-Hall, Paul Glavine, Michael Halstead and Eric Hoskins.
• Helus Pharma said the board has eight directors.
• The company said 46,452,598 common shares were represented.

Board

Helus Pharma said shareholders elected eight directors at its Sept. 22, 2026 meeting.

Helus Pharma elects eight directors, changes name Oct. 1

• Grant Froese was elected.
• Theresa Firestone was elected.
• Mark Lawson was elected.
• Eric So was elected.
• Freda Lewis-Hall was elected.
• Paul Glavine was elected.
• Michael Halstead was elected.
• Eric Hoskins was elected.

Company Details

The company said 46,452,598 common shares were represented at the meeting.

Helus Pharma said it is a commercial-ready pharmaceutical company and that HLP003 is in Phase 3 and HLP004 is in Phase 2.

Helus Pharma said its legal name change takes effect on October 1, 2026.

Zeifmans LLP was appointed auditor.

Helus Pharma said it has FDA breakthrough therapy designation.